International SARS-CoV-2 (COVID-19) Infection Observational Study
Public ClinicalTrials.gov record NCT04385251. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An International Observational Study of Outpatients With SARS-CoV-2 Infection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The general aim of this study is to estimate the rate of disease progression for adults testing positive for SARS-CoV-2. The primary endpoint for this study and the basis for sample size is hospitalization or death during the 28 day follow-up period. In some locations special facilities are being built/utilized for quarantine/public health reasons for those who are SARS-CoV-2 positive. Hospitalization is defined as a stay for at least 18 hours, irrespective of reason, at a hospital or one of these special facilities after study enrollment. Secondary outcomes include participant-reported health status and change in severity of dyspnoea.
Study identification
- NCT ID
- NCT04385251
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 11,973 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 17, 2020
- Primary completion
- Jan 30, 2022
- Completion
- Jan 30, 2022
- Last update posted
- Aug 15, 2022
2020 – 2022
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Denver Public Health | Denver | Colorado | 80204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
Recently updated COVID trials
Other public records listing COVID. Sorted by last update posted; newest first. Not a recommendation.
- NCT04362150: Long-term Impact of Infection With Novel Coronavirus (COVID-19) Recruiting
- NCT04568148: COVID-19 Biorepository Active, not recruiting
- NCT04910269: Outpatient Treatment With Anti-Coronavirus Immunoglobulin Recruiting
- NCT03452774: SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry Recruiting
- NCT07221097: Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses Recruiting
- NCT06744660: Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04385251, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 15, 2022 · Synced Sep 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04385251 live on ClinicalTrials.gov.